CTRI/2022/12/048356已完成未知
Evaluation of Skin Safety of test product using 24 Hours Patch Test Under CompleteOcclusion on Adult Healthy Human Participants with Non-Sensitive SkinIS 4011:2018 Guidelines.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Voluntary men and women (preferably equal number of males and females) between 18 and
- •2. Participants representing normal, oily, dry and combination skin type in approximately equal
- •3. Fitzpatrick skin type III to IV.
- •4. Having apparently healthy skin on test area.
- •5. Willingness to discontinue the use of cleansing and/or cosmetic products in the application
- •areas during the course of the trial
- •6. Cooperating, informed of the need and duration of the examinations, and ready to comply
- •with protocol procedures.
- •7. Willing to give written informed consent to participate in the trial after informing all
- •information concerning the trial procedures and trial objectives.
- •8. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course
- •of the trial.
- •9. Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.:
- •exercise, saunaâ?¦), during the course of the trial.
- •10. Should be able to read and write (in English, Hindi, or local language).
- •11. Ready to wear loose cotton clothes
- •12. Having valid proof of identity and age.
- •13. Subject having not participated in another trial in the past one month.
排除标准
- •1. Pregnancy (by history) and lactating women.
- •2. Scars, excessive terminal hair, or tattoo on the studied area.
- •3. A participant who the Investigator feels will not be compliant with trial requirements
- •4. Dermatological infection/pathology on the level of studied area.
- •5. Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).
- •6. Any clinically significant systemic or cutaneous disease, which may interfere with trial
- •procedures.
- •7. Chronic illness which may influence the outcome of the trial.
- •8. Participants on any medical treatment either systemic or topical which may interfere with the
- •performance of the trial (presently or in the past 1 month).
- •9. Participant in an exclusion period or participating in another food, cosmetic or therapeutic
研究者
相似试验
已完成
不适用
To study the safety of test products on humans.CTRI/2022/10/046691Dabur Research and Development Centre26
进行中(未招募)
4 期
To test the safety of test product by primary irritation patch test on Sensitive SkiCTRI/2023/05/053321Dabur India Limited
已完成
不适用
To study the safety of test products on skin in humans.CTRI/2023/02/049702Dabur India Limited26
已完成
不适用
To study the safety on test products on skin.CTRI/2022/11/047452Dabur Research and Development Centre26
已完成
Unknown
To study safety of a test product on humans.CTRI/2023/10/058542Dabur Research and Development Centre.26
